Global Treatment Resistant Depression Therapeutics Market 2025-2029
상품코드:1626161
리서치사:TechNavio
발행일:2024년 12월
페이지 정보:영문 201 Pages
라이선스 & 가격 (부가세 별도)
ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
한글목차
치료 저항성 우울증 치료 시장, 2025-2029년
치료 저항성 우울증 치료 시장은 2024-2029년에 20억 6,100만 달러, 예측 기간 중 CAGR은 6.1%로 성장할 것으로 예측됩니다. 치료 저항성 우울증 치료 시장의 전체적인 분석, 시장 규모·예측, 동향, 성장 촉진요인, 과제, 약 25개의 벤더를 다룬 벤더 분석 등을 게재하고 있습니다.
현재 시장 시나리오, 최신 동향과 촉진요인, 시장 환경 전체에 관한 최신 분석을 제공하고 있습니다. 우울증의 높은 유병률, 즉효성 항우울제에 대한 주력, 정신건강에 대한 투자 등이 시장을 촉진하고 있습니다.
시장 범위
기준년
2025년
종료년
2029년
예측 기간
2025-2029년
성장 모멘텀
가속
전년대비[2025년
5.8%
CAGR
6.1%
증분액
20억 6,100만 달러
본 조사에서는 향후 수년간 치료 저항성 우울증 치료 시장의 성장을 촉진하는 주요 요인의 하나로 의약품 개발에서 ai의 부상을 들고 있습니다. 또한 규제기관의 승인 증가 및 맞춤형 의료에 대한 주목도 시장의 큰 수요로 연결됩니다.
The treatment resistant depression therapeutics market is forecasted to grow by USD 2061 mn during 2024-2029, accelerating at a CAGR of 6.1% during the forecast period. The report on the treatment resistant depression therapeutics market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.
The report offers an up-to-date analysis regarding the current market scenario, the latest trends and drivers, and the overall market environment. The market is driven by high prevalence of depression, focus on rapid-acting antidepressants, and investments in mental health.
Market Scope
Base Year
2025
End Year
2029
Series Year
2025-2029
Growth Momentum
Accelerate
YOY 2025
5.8%
CAGR
6.1%
Incremental Value
$2061 mn
Technavio's treatment resistant depression therapeutics market is segmented as below:
By Distribution Channel
Offline
Online
By Type
Antidepressants
NMDA
Antipsychotics
Others
By Geographical Landscape
North America
Europe
Asia
Rest of World (ROW)
This study identifies the emergence of ai in drug development as one of the prime reasons driving the treatment resistant depression therapeutics market growth during the next few years. Also, increase in regulatory approvals and focus on personalized medicine will lead to sizable demand in the market.
The report on the treatment resistant depression therapeutics market covers the following areas:
Treatment Resistant Depression Therapeutics Market industry analysis
The robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading treatment resistant depression therapeutics market vendors that include AbbVie Inc., Acadia Pharmaceuticals Inc., Alkermes Public Ltd. Co., AstraZeneca Plc, Axsome Therapeutics Inc., Eli Lilly and Co., Evotec SE, H Lundbeck AS, Intra-Cellular Therapies Inc, Johnson and Johnson Inc., Numinus Wellness Inc, Otsuka Pharmaceutical Co. Ltd., Pfizer Inc., Sage Therapeutics Inc, Stella MSO LLC dba Field Trip Health, Sumitomo Pharma Co. Ltd., Teva Pharmaceutical Industries Ltd., and Vistagen Therapeutics Inc. Also, the treatment resistant depression therapeutics market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage all forthcoming growth opportunities.
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to an analysis of the key vendors.
The publisher presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive primary and secondary research. The market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast accurate market growth.
Table of Contents
1 Executive Summary
1.1 Market overview
Executive Summary - Chart on Market Overview
Executive Summary - Data Table on Market Overview
Executive Summary - Chart on Global Market Characteristics
Executive Summary - Chart on Market By Geographical Landscape
Executive Summary - Chart on Market Segmentation by Distribution Channel
Executive Summary - Chart on Market Segmentation by Type
Executive Summary - Chart on Incremental Growth
Executive Summary - Data Table on Incremental Growth
Executive Summary - Chart on Company Market Positioning
2 Technavio Analysis
2.1 Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria
Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria
2.2 Criticality of inputs and Factors of differentiation
Overview on criticality of inputs and factors of differentiation
2.3 Factors of disruption
Overview on factors of disruption
2.4 Impact of drivers and challenges
Impact of drivers and challenges in 2024 and 2029
3 Market Landscape
3.1 Market ecosystem
Parent Market
Data Table on - Parent Market
3.2 Market characteristics
Market characteristics analysis
3.3 Value chain analysis
Value chain analysis
4 Market Sizing
4.1 Market definition
Offerings of companies included in the market definition
4.2 Market segment analysis
Market segments
4.3 Market size 2024
4.4 Market outlook: Forecast for 2024-2029
Chart on Global - Market size and forecast 2024-2029 ($ million)
Data Table on Global - Market size and forecast 2024-2029 ($ million)
Chart on Global Market: Year-over-year growth 2024-2029 (%)
Data Table on Global Market: Year-over-year growth 2024-2029 (%)
5 Historic Market Size
5.1 Global Treatment Resistant Depression Therapeutics Market 2019 - 2023
Historic Market Size - Data Table on Global Treatment Resistant Depression Therapeutics Market 2019 - 2023 ($ million)
5.2 Distribution Channel segment analysis 2019 - 2023
